How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

6,443 results for

fluoroquinolones

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Fluoroquinolones: use should be restricted due to severe adverse effects

Fluoroquinolones: use should be restricted due to severe adverse effects Prescrire IN ENGLISH - Spotlight '' Fluoroquinolones: use should be restricted due to severe adverse effects'', 1 September 2019 {1} {1} {1} | | > > > Fluoroquinolones: use should be restricted due to severe adverse effects Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight (...) Fluoroquinolones: use should be restricted due to severe adverse effects Given the many and sometimes severe adverse effects of fluoroquinolone antibiotics, they should only be used for limited purposes. Fluoroquinolones are a group of antibiotics that are effective on many bacteria. But their adverse effects are many and sometimes severe, which has led to the gradual limitation of their use. The European Pharmacovigilance Committee (PRAC) reassessed all adverse reactions to fluoroquinolones in 2018

2019 Prescrire

2. Fluoroquinolones for the Treatment of Otitis Media: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Fluoroquinolones for the Treatment of Otitis Media: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Fluoroquinolones for the Treatment of Otitis Media: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Fluoroquinolones for the Treatment of Otitis Media: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Fluoroquinolones for the Treatment of Otitis Media: A Review of Clinical Effectiveness (...) , Cost-Effectiveness, and Guidelines Last updated: April 24, 2019 Project Number: RC1095-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of fluoroquinolones for the treatment of otitis media in patients unable to take beta-lactams antibiotics? What is the cost-effectiveness of fluoroquinolones for the treatment of otitis media in patients unable to take beta-lactams antibiotics? What are the evidence

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

3. Fluoroquinolones for the Treatment of Intra-Abdominal Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Fluoroquinolones for the Treatment of Intra-Abdominal Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Fluoroquinolones for the Treatment of Intra-Abdominal Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Fluoroquinolones for the Treatment of Intra-Abdominal Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Fluoroquinolones for the Treatment of Intra (...) -Abdominal Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Last updated: April 25, 2019 Project Number: RC1094-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of fluoroquinolones for the treatment of intra-abdominal infections? What is the cost-effectiveness of fluoroquinolones for the treatment of intra-abdominal infections? What are the evidence-based guidelines

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

4. Fluoroquinolones for the Treatment of Urinary Tract Infection: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Fluoroquinolones for the Treatment of Urinary Tract Infection: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Fluoroquinolones for the Treatment of Urinary Tract Infection: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Fluoroquinolones for the Treatment of Urinary Tract Infection: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Fluoroquinolones for the Treatment of Urinary Tract (...) Infection: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Last updated: April 26, 2019 Project Number: RC1101-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of fluoroquinolones for the treatment of urinary tract infections? What is the cost-effectiveness of fluoroquinolones for the treatment of urinary tract infections? What are the evidence-based guidelines regarding the use

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

5. Fluoroquinolones for the Treatment of Respiratory Tract Infections: A Review of Clinical Effectiveness,

Fluoroquinolones for the Treatment of Respiratory Tract Infections: A Review of Clinical Effectiveness, Fluoroquinolones for the Treatment of Respiratory Tract Infections: A Review of Clinical Effectiveness, | CADTH.ca Find the information you need Fluoroquinolones for the Treatment of Respiratory Tract Infections: A Review of Clinical Effectiveness, Fluoroquinolones for the Treatment of Respiratory Tract Infections: A Review of Clinical Effectiveness, Last updated: May 6, 2019 Project Number (...) : RC1093-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of fluoroquinolones for the treatment of respiratory tract infections? What is the cost-effectiveness of fluoroquinolones for the treatment of respiratory tract infections? What are the evidence-based guidelines for the use of fluoroquinolones for the treatment of respiratory tract infections? Key Message Overall, 15 publications met the eligibility

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

6. Fluoroquinolones for the Treatment of Other Respiratory Tract Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Fluoroquinolones for the Treatment of Other Respiratory Tract Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Fluoroquinolones for the Treatment of Other Respiratory Tract Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Fluoroquinolones for the Treatment of Other Respiratory Tract Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Fluoroquinolones (...) for the Treatment of Other Respiratory Tract Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Last updated: May 31, 2019 Project Number: RC1123-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of fluoroquinolones for the treatment of ‘other’ respiratory tract infections? What is the cost-effectiveness of fluoroquinolones for the treatment of ‘other’ respiratory tract infections

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

7. Practice Advisory: FDA Warning About Fluoroquinolones and Risk of Aortic Ruptures or Tears

Practice Advisory: FDA Warning About Fluoroquinolones and Risk of Aortic Ruptures or Tears Practice Advisory: FDA Warning About Fluoroquinolones and Risk of Aortic Ruptures or Tears - ACOG Menu ▼ Practice Advisory: FDA Warning About Fluoroquinolones and Risk of Aortic Ruptures or Tears Page Navigation ▼ Share: Practice Advisory: FDA Warning About Fluoroquinolones and Risk of Aortic Ruptures or Tears (Replaces July 20, 2018, ACOG Practice Advisory, “New FDA Safety Warning for Fluoroquinolone (...) Antibiotics”) The U.S. Food and Drug Administration (FDA) has updated its drug safety information for oral and injectable fluoroquinolone antibiotics to include the rare but serious risk of aortic ruptures or tears in certain patients (1). The FDA advises that health care providers should not prescribe systemic fluoroquinolones for patients who have an aortic aneurysm or are at risk of an aortic aneurysm (such as patients with peripheral atherosclerotic vascular diseases, hypertension, certain genetic

2019 American College of Obstetricians and Gynecologists

8. FDA Warning About Fluoroquinolones and Risk of Aortic Ruptures or Tears

FDA Warning About Fluoroquinolones and Risk of Aortic Ruptures or Tears FDA Warning About Fluoroquinolones and Risk of Aortic Ruptures or Tears | ACOG Clinical Guidance Journals & Publications Patient Education Topics Featured Clinical Topics Hi, Featured Clinical Topics Clinical Guidance FDA Warning About Fluoroquinolones and Risk of Aortic Ruptures or Tears Practice Advisory November 2019 Jump to Resources Share By reading this page you agree to ACOG's Terms and Conditions. . The FDA advises (...) that health care providers should not prescribe systemic fluoroquinolones for patients who have an aortic aneurysm or are at risk of an aortic aneurysm (such as patients with peripheral atherosclerotic vascular diseases, hypertension, certain genetic conditions such as Marfan syndrome and Ehlers-Danlos syndrome, and elderly patients) unless no other treatments are available . This updated warning will be added to the prescribing information and patient medication guide for all fluoroquinolones

2019 American College of Obstetricians and Gynecologists

9. Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects

Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports (...) of disabling and potentially long-lasting or irreversible side effects Disabling, long-lasting or potentially irreversible adverse reactions affecting musculoskeletal and nervous systems have been reported very rarely with fluoroquinolone antibiotics. Fluoroquinolone treatment should be discontinued at the first signs of a serious adverse reaction, including tendon pain or inflammation. Published 21 March 2019 From: Therapeutic area: , , , , , , , , , , , , , Contents Advice for healthcare professionals

2019 MHRA Drug Safety Update

11. Fluoroquinolone resistance in Escherichia coli isolates after exposure to non-fluoroquinolone antibiotics: a retrospective case-control study. (Abstract)

Fluoroquinolone resistance in Escherichia coli isolates after exposure to non-fluoroquinolone antibiotics: a retrospective case-control study. To investigate whether prior exposure to non-fluoroquinolone antibiotics increases the risk of fluoroquinolone resistance in Escherichia coli.This was a secondary analysis of data collected retrospectively in a case-control study linking microbiological test results (isolated bacteria and their susceptibility) of urine samples routinely collected from (...) primary, secondary and tertiary care patients in Belgium with information on prior antibiotic use at the patient level up to 1 year previously.In urine samples from 6125 patients, 7204 E. coli isolates were retrieved [1949 fluoroquinolone-resistant isolates (cases) and 5255 fluoroquinolone-susceptible isolates (controls)]. After adjusting for potential confounders (including fluoroquinolone use) and correcting for multiple testing there were lower odds of fluoroquinolone resistance in E. coli isolates

2020 Journal of Antimicrobial Chemotherapy

12. <i>In Vitro</i> Derivation of Fluoroquinolone-Resistant Mutants from Multiple Lineages of Haemophilus influenzae and Identification of Mutations Associated with Fluoroquinolone Resistance. Full Text available with Trip Pro

In Vitro Derivation of Fluoroquinolone-Resistant Mutants from Multiple Lineages of Haemophilus influenzae and Identification of Mutations Associated with Fluoroquinolone Resistance. Haemophilus influenzae is a pathogenic bacterium that causes respiratory and otolaryngological infections. The increasing prevalence of β-lactamase-negative high-level ampicillin-resistant H. influenzae (high-BLNAR) is a clinical concern. Fluoroquinolones are alternative agents to β-lactams. However (...) , the emergence and increasing prevalence of fluoroquinolone-resistant H. influenzae have been reported. The current risk of fluoroquinolone resistance in H. influenzae (especially in high-BLNAR) has not yet been evaluated. Here, we examined the development of fluoroquinolone resistance in fluoroquinolone-susceptible clinical H. influenzae isolates in vitro during passaging in the presence of moxifloxacin (from 0.03 to 128 mg/liter). Twenty-nine isolates were examined. Seventeen isolates (58.6%) showed

2020 Antimicrobial Agents and Chemotherapy

13. Inpatient fluoroquinolone use in Veterans' Affairs hospitals is a predictor of <i>Clostridioides difficile</i> infection due to fluoroquinolone-resistant ribotype 027 strains. (Abstract)

Inpatient fluoroquinolone use in Veterans' Affairs hospitals is a predictor of Clostridioides difficile infection due to fluoroquinolone-resistant ribotype 027 strains. Reduction in the use of fluoroquinolone antibiotics has been associated with reductions in Clostridioides difficile infections (CDIs) due to fluoroquinolone-resistant strains.To determine whether facility-level fluoroquinolone use predicts healthcare facility-associated (HCFA) CDI due to fluoroquinolone-resistant 027 (...) strains.Using a nationwide cohort of hospitalized patients in the Veterans' Affairs Healthcare System, we identified hospitals that categorized >80% of CDI cases as positive or negative for the 027 strain for at least one-quarter of fiscal years 2011-2018. Within these facilities, we used visual summaries and multilevel logistic regression models to assess the association between facility-level fluoroquinolone use and rates of HCFA-CDI due to 027 strains, controlling for time and facility complexity level

2020 Infection control and hospital epidemiology

14. Inpatient Fluoroquinolone Stewardship Improves the Quantity and Quality of Fluoroquinolone-prescribing at Hospital Discharge: A Retrospective Analysis among 122 Veterans Health Administration Hospitals. Full Text available with Trip Pro

Inpatient Fluoroquinolone Stewardship Improves the Quantity and Quality of Fluoroquinolone-prescribing at Hospital Discharge: A Retrospective Analysis among 122 Veterans Health Administration Hospitals. Despite increasing awareness of harms, fluoroquinolones are still frequently prescribed to inpatients and at hospital discharge. Our goal was to describe fluoroquinolone-prescribing at hospital discharge across the Veterans Health Administration (VHA) and to contrast fluoroquinolone-prescribing (...) volume and appropriateness across 3 antimicrobial stewardship strategy-types.We analyzed a retrospective cohort of patients hospitalized at 122 VHA acute-care hospitals during 2014-2016. Data from a mandatory VHA survey were used to identify 9 hospitals that self-reported one of 3 strategies for optimizing fluoroquinolone-prescribing: prospective audit-and-feedback (PAF), restrictive policies (RP), and no strategy. Manual chart reviews to assess fluoroquinolone appropriateness at hospital discharge

2019 Clinical Infectious Diseases

15. Systemic and inhaled fluoroquinolones: small increased risk of aortic aneurysm and dissection; advice for prescribing in high-risk patients Full Text available with Trip Pro

Systemic and inhaled fluoroquinolones: small increased risk of aortic aneurysm and dissection; advice for prescribing in high-risk patients Systemic and inhaled fluoroquinolones: small increased risk of aortic aneurysm and dissection; advice for prescribing in high-risk patients - GOV.UK GOV.UK uses cookies to make the site simpler. Search Systemic and inhaled fluoroquinolones: small increased risk of aortic aneurysm and dissection; advice for prescribing in high-risk patients In patients (...) at risk for aortic aneurysm and dissection, fluoroquinolones should only be used after careful assessment of the benefits and risks and after consideration of other therapeutic options. Published 14 November 2018 From: Therapeutic area: , , Contents Advice for healthcare professionals: systemic (by mouth or injection) and inhaled fluoroquinolones may be associated with a small increased risk of aortic aneurysm and dissection, particularly in older patients fluoroquinolones should only be used after

2018 MHRA Drug Safety Update

16. Relationship between fluoroquinolones and the risk of aortic diseases: a meta-analysis of observational studies Full Text available with Trip Pro

Relationship between fluoroquinolones and the risk of aortic diseases: a meta-analysis of observational studies Relationship between fluoroquinolones and the risk of aortic diseases: a meta-analysis of observational studies | Research Square Browse Tools & Services Your Cart This preprint is under consideration at BMC Cardiovascular Disorders . A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior (...) to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article Relationship between fluoroquinolones and the risk of aortic diseases: a meta-analysis of observational studies Xiao-ce Dai, Xin-xin Yang, Lan Ma, Guan-min Tang, Yan-yun Pan, Hui-lin Hu Xiao-ce Dai First Hospital of Jiaxing Xin-xin Yang Zhejiang Hospital of Traditional

2020 Research Square

17. Relationship between fluoroquinolones and the risk of aortic diseases: a meta-analysis of observational studies Full Text available with Trip Pro

Relationship between fluoroquinolones and the risk of aortic diseases: a meta-analysis of observational studies Relationship between fluoroquinolones and the risk of aortic diseases: a meta-analysis of observational studies | Research Square Browse Tools & Services Your Cart This preprint is under consideration at BMC Cardiovascular Disorders . A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior (...) to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Technical advance Relationship between fluoroquinolones and the risk of aortic diseases: a meta-analysis of observational studies Xiao-ce Dai, Xin-xin Yang, Lan Ma, Guan-min Tang, Yan-yun Pan, Hui-lin Hu Xiao-ce Dai First Hospital of Jiaxing Xin-xin Yang Zhejiang Hospital of Traditional

2020 Research Square

18. Bacterial antibiotic resistance development and mutagenesis following exposure to subinhibitory concentrations of fluoroquinolones in vitro: a systematic review of the literature Full Text available with Trip Pro

Bacterial antibiotic resistance development and mutagenesis following exposure to subinhibitory concentrations of fluoroquinolones in vitro: a systematic review of the literature Bacterial antibiotic resistance development and mutagenesis following exposure to subinhibitory concentrations of fluoroquinolones in vitro: a systematic review of the literature | JAC-Antimicrobial Resistance | Oxford Academic ') We use cookies to enhance your experience on our website.By continuing to use our website (...) , you are agreeing to our use of cookies. You can change your cookie settings at any time. Advertisement Navbar Search Filter Mobile Microsite Search Term search filter search input Article Navigation Close mobile search navigation Article Navigation September 2020 Article Contents Article Navigation Bacterial antibiotic resistance development and mutagenesis following exposure to subinhibitory concentrations of fluoroquinolones in vitro : a systematic review of the literature , Carly Ching

2020 JAC-Antimicrobial Resistance

19. Association of Infections and Use of Fluoroquinolones With the Risk of Aortic Aneurysm or Aortic Dissection

Association of Infections and Use of Fluoroquinolones With the Risk of Aortic Aneurysm or Aortic Dissection Association of Infections and Use of Fluoroquinolones With the Risk of Aortic Aneurysm or Aortic Dissection - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest (...) of Fluoroquinolones With the Risk of Aortic Aneurysm or Aortic Dissection , , , , , Affiliations Expand Affiliations 1 Faculty of Pharmacy, National Yang-Ming University School of Pharmaceutical Science, Taipei, Taiwan. 2 Institute of Public Health, National Yang-Ming University School of Medicine, Taipei, Taiwan. 3 Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. 4 Department of Medicine, National Taiwan University College of Medicine, Taipei, Taiwan. 5 Institute

2020 EvidenceUpdates

20. Fluoroquinolone Prescribing and Use in Canadian Primary Care Practice

Fluoroquinolone Prescribing and Use in Canadian Primary Care Practice Fluoroquinolone Prescribing and Use in Canadian Primary Care Practice | CADTH.ca Find the information you need Fluoroquinolone Prescribing and Use in Canadian Primary Care Practice Fluoroquinolone Prescribing and Use in Canadian Primary Care Practice Last updated: May 1, 2017 Project Number: HT0018-000 - CP0020-000 Product Line: Technology Review Result type: Report The study investigated current practices and implementation (...) issues for antibiotic therapies, particularly fluoroquinolones, for specific indications. The study was conducted from the perspective of family physicians, nurse practitioners, and pharmacists. Indications included: uncomplicated cystitis, uncomplicated pyelonephritis, acute bacterial exacerbation of chronic bronchitis in chronic obstructive pulmonary disease (COPD), and acute bacterial sinusitis. The research findings are based on the results of qualitative research in the form of surveys

2017 CADTH - Technology Review

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>